← Browse by Condition
Medical Condition

esophageal neoplasms

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for esophageal neoplasms sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — esophageal neoplasms Clinical Trials

How many clinical trials are currently recruiting for esophageal neoplasms?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for esophageal neoplasms, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for esophageal neoplasms?
esophageal neoplasms research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a esophageal neoplasms clinical trial?
Eligibility criteria for esophageal neoplasms trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
Jiangxi Provincial Cancer Hospital 1 trial
Mayo Clinic 1 trial
Yonsei University 1 trial

Recruiting Clinical Trials

NCT05252078 Phase 2
Recruiting
Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
Enrollment
30 pts
Location
China
Sponsor
Jiangxi Provincial Cancer Hosp...
View Trial →
NCT02530983
Recruiting
Mayo Clinic Upper Digestive Disease Survey
Enrollment
1,000 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT07035587
Recruiting
Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques
Enrollment
1,200 pts
Location
South Korea
Sponsor
Yonsei University
View Trial →

Related Conditions

esophageal squamous cell carcinoma (1) esophageal diseases (1) gastrointestinal neoplasms (1) gastrointestinal diseases (1) digestive system neoplasms (1) digestive system diseases (1) neoplasms by site (1) neoplasms by histologic type (1) neoplasms squamous cell (1) carcinoma squamous cell (1) cancer of esophagus (1) cancer of the esophagus (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology